Avapritinib

• Description:

  Avapritinib is an inhibitor of oncogenic KIT and PDGFRA mutations. The KIT receptor belongs to the class III receptor tyrosine kinase (RTK) family. Avapritinib potently inhibits the activation loop mutants KIT D816V and PDGFRA D842V and also inhibits other well-characterized disease-driving KIT mutants. It inhibits KIT D816V and PDGFRA D842V with IC₅₀ values of 0.27 nM and 0.24 nM respectively. Avapritinib (0.3-30 mg/kg) reduces tumor volume in a P815 KIT D814Y mastocytoma allograft mouse model and a GIST patient-derived mouse xenograft model in a dose-dependent manner. It has showed marked activity in patients with diseases associated with KIT (aggressive systemic mastocytosis and gastrointestinal stromal tumor) and PDGFRA (gastrointestinal stromal tumor) activation loop mutations in a phase 1 clinical study.

• Shipping Conditions:

  RT

• Storage Conditions:

  -20ºC

• Shelf Life:

  36 months